iShares Biotechnology ETF
370 hedge funds and large institutions have $5.12B invested in iShares Biotechnology ETF in 2014 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 107 increasing their positions, 114 reducing their positions, and 28 closing their positions.
196% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 28
47% more funds holding in top 10
Funds holding in top 10: 17 → 25 (+8)
16% more funds holding
Funds holding: 318 → 370 (+52)
2% less capital invested
Capital invested by funds: $5.2B → $5.12B (-$79.3M)
6% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 114
45% less call options, than puts
Call options by funds: $448M | Put options by funds: $821M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$374M |
| 2 |
BFA
Beaumont Financial Advisors
Needham,
Massachusetts
|
+$64.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$53.3M |
| 4 |
AssetMark Inc
Concord,
California
|
+$38.7M |
| 5 |
Jane Street
New York
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$509M |
| 2 |
Citigroup
New York
|
-$302M |
| 3 |
Morgan Stanley
New York
|
-$164M |
| 4 |
Barclays
London,
United Kingdom
|
-$143M |
| 5 |
JP Morgan Chase
New York
|
-$87.1M |
IBB Hedge Fund Activity: Q4 2014 in Review
370 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2014, worth a combined $5.12B — down 1.5% from $5.2B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new IBB positions and 28 closed out — a net gain of 55 holders — while 107 added to existing stakes and 114 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $374M. The largest seller was Goldman Sachs, cutting an estimated $509M.
- 370 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2014, up from 318 in Q3 2014.
- Funds reported $5.12B of iShares Biotechnology ETF stock for Q4 2014, down 1.5% quarter-over-quarter.
- 83 funds opened new iShares Biotechnology ETF positions in Q4 2014 and 28 closed out, a net change of +55 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2014 was Deutsche Bank, an estimated $374M added.
- The largest iShares Biotechnology ETF seller in Q4 2014 was Goldman Sachs, an estimated $509M sold.
Based on aggregated 13F filings for Q4 2014.